5. Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

​

In August 2025, the Company announced cost reduction initiatives to reduce planned operating costs, primarily through a workforce reduction. As of December 31, 2025, the workforce reduction is substantially completed and the Company recognized aggregate charges for severance and other employee termination benefits of $5.3 million during the year ended December 31, 2025, of which $4.2 million were included in research and development expenses and $1.1 million were included in general and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss. Of the charges recognized during the year ended December 31, 2025, $5.0 million represented

cash expenditure for severance and other employee termination benefits paid during the period, and the remaining $0.3 million in unpaid benefits are included in accrued employee compensation and benefits within accrued expenses and other current liabilities in the Company’s consolidated balance sheet as of December 31, 2025.

​

In August 2024, the Company consolidated all discovery research activities to the Company’s headquarters in Cambridge, U.K. As a result, during the year ended December 31, 2024, the Company recognized charges of $2.0 million in severance and other one-time termination benefits, which are included in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, of which $1.6 million were paid during the year ended December 31, 2024, and the Company had a remaining liability of $0.4 million related to unpaid severance and other one-time termination benefits included in accrued expenses and other current liabilities in the Company’s consolidated balance sheet as of December 31, 2024, all of which was paid during the year ended December 31, 2025.